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ABSTRACT
High-risk endometrial cancer (EC) is an aggressive disease for which new therapeutic options are needed.
Aims of this study were to validate the enhanced immune response in highly mutated ECs and to explore
immune proﬁles in other EC subgroups. We evaluated immune inﬁltration in 116 high-risk ECs from the
TransPORTEC consortium, previously classiﬁed into four molecular subtypes: (i) ultramutated POLE
exonuclease domain-mutant ECs (POLE-mutant); (ii) hypermutated microsatellite unstable (MSI); (iii) p53-
mutant; and (iv) no speciﬁc molecular proﬁle (NSMP). Within The Cancer Genome Atlas (TCGA) EC cohort,
signiﬁcantly higher numbers of predicted neoantigens were demonstrated in POLE-mutant and MSI tumors
compared with NSMP and p53-mutants. This was reﬂected by enhanced immune expression and inﬁltration
in POLE-mutant and MSI tumors in both the TCGA cohort (mRNA expression) and the TransPORTEC cohort
(immunohistochemistry) with high inﬁltration of CD8C (90% and 69%), PD-1C (73% and 69%) and PD-L1C
immune cells (100% and 71%). Notably, a subset of p53-mutant and NSMP cancers was characterized by signs
of an antitumor immune response (43% and 31% of tumors with high inﬁltration of CD8C cells, respectively),
despite a low number of predicted neoantigens. In conclusion, the presence of enhanced immune inﬁltration,
particularly high numbers of PD-1 and PD-L1 positive cells, in highly mutated, neoantigen-rich POLE-mutant








The development of novel immunotherapeutic strategies such
as checkpoint inhibitors has the potential to transform the ﬁeld
of oncology. So far, durable responses have been established in
subsets of patients, for example with metastatic melanoma,
non-small cell lung cancer, and mismatch repair-deﬁcient can-
cers including two patients with endometrial cancer (EC).1-7
Although the clinical efﬁcacy of immune checkpoint inhibitors
is evident in a subset of patients, selecting the patients who
may beneﬁt from this therapy remains challenging. A key
mechanism for the beneﬁt of immune checkpoint inhibition in
these cancers is the induction of a strong neoantigen-driven
T-cell response against the tumor. Indeed, comprehensive anal-
ysis of large genomic datasets such as The Cancer Genome
Atlas (TCGA) have provided a clear link between mutational
load and activation of the immune system, implicating the
involvement of neoantigens in driving cytotoxic T-cell
responses in cancer.8-10 Furthermore, several clinical trials have
shown a strong association between the presence of high num-
bers of predicted neoantigens, immune inﬁltration and
response to cancer immunotherapy.11-15 In particular, the pres-
ence of CD8C cytotoxic T cells and expression of the immune
checkpoints PD-1 and PD-L1 have been proposed as important
predictors of objective tumor regression.3,16
Characterization of the immune contexture of individual
tumors may provide guidance in selecting appropriate immu-
notherapy for each individual patient, especially when inte-
grated with an analysis of genomic alterations.10,17,18
A molecular classiﬁcation has recently been proposed by The
Cancer Genome Atlas (TCGA), which identiﬁed four genomi-
cally distinct EC subgroups: an ultramutated group character-
ized by somatic mutations in the exonuclease domain of POLE
(encoding the catalytic subunit of DNA polymerase epsilon), a
microsatellite unstable (MSI) hypermutated group with many
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substitutions as well as insertions and deletions due to mis-
match repair deﬁciency, a copy-number high (serous-like)
group with frequent TP53 mutation and a copy-number low
(microsatellite stable (MSS)) group with no speciﬁc molecular
proﬁle (NSMP).19
In line with this, we, and others, have recently demonstrated
high numbers of predicted immunogenic mutations and
enhanced antitumor immune inﬁltration in ultramutated
POLE-mutant and, to a lesser extent, in hypermutated micro-
satellite unstable EC.20-23 These studies combined with the
emerging data linking mutational load, immune activation and
response to cancer immunotherapy render POLE-mutated and
MSI cancers plausible candidates for immune checkpoint inhi-
bition.3,10-13,24 This is further underlined by recent case reports
demonstrating the efﬁcacy of anti-PD-1 inhibitors in advanced
POLE-mutant or mismatch repair deﬁcient cancers, including
those of endometrial origin.7,25,26
In this study, we aimed to validate our previous ﬁndings of
an enhanced immune response in POLE-mutant and MSI
endometrial cancers in a cohort of high-risk patients. High-
risk EC patients are a particularly relevant subgroup, as most
have no or only very modest gain from standard local or sys-
temic treatment after surgery. Novel treatment options are
therefore urgently needed. The use of a molecularly deﬁned
cohort of high-risk endometrial cancer also enabled us to
explore the immune proﬁles of the poorly characterized
NMSP and p53-mutant subgroups. With this approach we
provide a rationale for the administration of checkpoint inhi-
bition strategies in subsets of POLE-mutant and MSI endome-
trial cancer patients.
Results
Enhanced inﬁltration of intratumoral CD3C, CD8C and
CD103C lymphocytes in POLE-mutant and MSI tumors
We ﬁrst sought to characterize the lymphocytic inﬁltrate in
the four EC molecular subtypes by immunohistochemical
analysis of CD3C, CD8C, CD103C and CD20C (Fig. 1A and
B). Compared to NSMP and p53-mutant tumors, both POLE-
mutant and MSI tumors demonstrated increased density of
CD3C T-lymphocytes within the tumor center (POLE vs
Figure 1. Inﬁltration of CD3C, CD8C, CD103C and CD27C cells in POLE-mutant, MSI, NSMP and p53-mutant endometrial cancers. (A) Representative immunohistochemical
stainings of CD3C, CD8C, CD103C and CD20C cells. (B) Average number of positively stained intratumoral cells for each of the markers in the above panel, counted per
core, corrected for the number of cells present. (C) Average number of positively stained cells for each of the markers in the above panel, counted per core within the inﬁl-
trative margin, corrected for the number of cells present. The numbers of cases analyzed for each molecular subgroup are listed below the x-axis. Boxes represent the
interquartile range (IQR), with the upper whisker indicating the 75th percentile and the lower whisker the 25th percentile. The median and mean values are indicated by
a horizontal line and cross, respectively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite unstable; NSMP, no speciﬁc molecular proﬁle; p53, p53-mutant. p < 0.05,
p < 0.01, p < 0.001.
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NSMP p D 0.002, MSI vs NSMP p D 0.001, MSI vs p53 p D
0.018). Staining for cytotoxic T-lymphocyte marker CD8C
and the intraepithelial T-lymphocyte marker CD103C
revealed similarly increased inﬁltrate in the tumor center
(comparison of CD8C cells: POLE vs NSMP p < 0.001; POLE
vs p53 p D 0.021; MSI vs NSMP p D 0.016, comparison of
CD103C cells: POLE vs MSI p D 0.023; MSI vs NSMP p D
0.035; MSI vs p53 p D 0.030). Based on a median of 80.5
CD8C cells/core in the whole cohort, 90% of POLE-mutant,
69% of MSI, 31% of NSMP and 43% of p53-mutant tumors
were categorized as highly inﬁltrated with CD8C cells. There
was no difference in numbers of CD20C B-lymphocytes
within the tumor center. A combined analysis in which the
two molecular subgroups with a high expected neoantigen
load (POLE-mutant and MSI) were compared with the two
molecular subgroups with lower expected neoantigen load
(NSMP and p53-mutant), supported the apparent differences
in immune inﬁltrate between EC subtypes (Fig. S1A).
Within the inﬁltrative margin, CD3C, CD8C, CD103C or
CD20C inﬁltration did not signiﬁcantly differ between the four
molecular subgroups (Fig. 1C). Combined analysis showed a
higher inﬁltration of CD8C and CD103C in POLE-mutant and
MSI (CD8C p D 0.010, CD103 p D 0.016, Fig. S1B).
Increased inﬁltration of CD45ROC and TIA-1C lymphocytes
in MSI tumors
To analyze the function of the tumors’ lymphocytic inﬁltrate,
we performed immunohistochemistry for CD45RO, CD27,
T-Bet and TIA-1 (Fig. 2A and B). Within the tumor center,
MSI tumors contained more CD45ROC memory T-lympho-
cytes compared with NSMP and p53-mutant tumors (MSI vs
NSMP p D 0.029, MSI vs p53 p D 0.008). MSI tumors also har-
bored more TIA-1C cytolytic lymphocytes within the tumor
center (MSI vs NSMP p D 0.019, MSI vs p53 p D 0.043). There
were no differences in the numbers of CD27C naive T cells and
T-BetC differentiated cells between the four molecular sub-
groups. Combined analysis of molecular groups revealed the
presence of more CD45ROC and TIA-1C cells in POLE-
mutant/MSI tumors compared with NSMP/p53-mutant
Figure 2. Inﬁltration of TIA-1C, T-BetC, CD20C and CD45ROC cells in POLE-mutant, MSI, NSMP and p53-mutant endometrial cancers. (A) Representative immunohisto-
chemical stainings of CD45ROC, CD27C, T-BetC and TIA-1C cells. (B) Average number of positively stained intratumoral cells for each of the markers in the above panel,
counted per core within the tumor center, corrected for the number of cells present. (C) Average number of positively stained cells for each of the markers in the above
panel, counted per core within the inﬁltrative margin, corrected for the number of cells present. The numbers of cases analyzed for each molecular subgroup are listed
below the x-axis. Boxes represent the interquartile range (IQR), with the upper whisker indicating the 75th percentile and the lower whisker the 25th percentile. The
median and mean values are indicated by a horizontal line and cross, respectively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite unstable; NSMP, no speciﬁc
molecular proﬁle; p53, p53-mutant. p < 0.05, p < 0.01, p < 0.001.
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tumors (Fig. S2A). Moreover, this also demonstrated higher
numbers of T-BetC differentiated cells within POLE-mutant/
MSI tumors compared with NSMP/p53-mutant tumors (p D
0.021).
Concordant with our ﬁndings in the tumor center, the
inﬁltrative margin of MSI tumors contained more
CD45ROC lymphocytes (MSI vs NSMP p D 0.002, MSI vs
p53 p D 0.003) and more TIA-1C cytolytic T-lymphocytes
(MSI vs NSMP p D 0.002, Fig. 2C). NSMP tumors demon-
strated more TIA-1C lymphocytes compared with p53-
mutant tumors (NSMP vs p53 p D 0.023). The numbers of
CD27C and T-BetC cells did not signiﬁcantly differ
between the four molecular subgroups. Data from the com-
bined analyses supported the increased density of
CD45ROC and TIA-1C cells within POLE-mutant/MSI
tumors (Fig. S2B).
Increase in inﬁltration of PD-1C and PD-L1C lymphocytes
in POLE-mutant and MSI tumors
The increased lymphocytic inﬁltrate of POLE-mutant and MSI
tumors, in combination with their expected ultramutated
Figure 3. Inﬁltration of PD-1C and PD-L1C cells in POLE-mutant, MSI, NSMP and p53-mutant endometrial cancers. (A) Representative immunohistochemical stainings of
PD-1C and PD-L1C cells. (B) Average number of PD1C cells counted per core within the tumor center, corrected for the number of cells present. (C) Percentage of PD-L1C
tumor-inﬁltrating immune cells within the tumor core and inﬁltrative margin core. (D) Average number of PD1C stained cells counted per core within the inﬁltrative mar-
gin. The numbers of cases analyzed for each molecular subgroup are listed below the x-axis. Boxes represent the interquartile range (IQR), with the upper whisker indicat-
ing the 75th percentile and the lower whisker the 25th percentile. The median and mean values are indicated by a horizontal line and cross, respectively. Abbreviations:
POLE, POLE-mutant; MSI, microsatellite unstable; NSMP, no speciﬁc molecular proﬁle; p53, p53-mutant. p < 0.05, p< 0.01, p < 0.001.
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(POLE-mutant tumors) or hypermutated (MSI tumors) status,
prompted us to investigate the presence of PD-1C and PD-L1C
cells within this cohort (Fig. 3A).
The tumor center of POLE-mutant and MSI tumors har-
bored high numbers of PD-1C immune cells (POLE vs NSMP
p < 0.001, POLE vs p53 p D 0.050, and MSI vs NSMP p D
0.003, Fig. 3B). This was supported by the combined analysis
(Fig. S3A). Based on a median of 14.0 PD-1C cells/core in all
patients, 73% of POLE-mutant, 69% of MSI, 31% of NSMP and
48% of p53-mutant tumors were categorized as highly inﬁl-
trated with PD-1C cells.
POLE-mutant and MSI tumors showed markedly increased
inﬁltration of PD-L1C immune cells within the tumor center
compare with NSMP and p53-mutant tumors (POLE vs NSMP
p < 0.001, POLE vs p53 p < 0.001, MSI vs NSMP p < 0.001,
MSI vs p53 p D 0.002, Fig. 3C). The combined analysis showed
similar results (Fig. S3B). In total, 100% of POLE-mutant, 71%
of MSI, 18% of NSMP and 29% of p53-mutant tumors were
categorized as PD-L1C (based on the immune score). Strik-
ingly, only one tumor sample, a p53-mutant EC, contained
PD-L1 expressing tumor cells (noted as a positive tumor score,
data not shown).
Within the inﬁltrative margin, only the POLE-mutant sub-
group showed high densities of PD-1C immune cells (POLE vs
NSMP p D 0.008, POLE vs p53 p D 0.007, Fig. 3D). Combined
analysis supported the presence of high numbers of PD-1C cells
within the POLE-mutant/MSI group compare with the NSMP/
p53-mutant group (Fig. S3C).
PD-L1 is preferentially expressed on myeloid cells
Recently, several studies have shown PD-L1 expression on
tumor-associated myeloid cells.1,27-30 Therefore, to determine
whether this was also the case for our cohort, we performed
two multi-color immunoﬂuorescence stainings on consecutive
whole slides of a highly inﬁltrated POLE-mutant tumor sample
using the following combinations of monoclonal antibodies:
CD68–CD163 – epithelial cell marker cytokeratin, and PD-L1–
PD-1, respectively (Fig. 4). CD68C and/or CD163C myeloid
cells (including macrophages and myeloid dendritic cells) were
found in the stromal regions within the center of the tumor,
demarcated by the cytokeratinC tumor cells (Fig. 4A). PD-1C
and PD-L1C cells were seen in close proximity, also predomi-
nantly located in the intratumoral stromal areas (Fig. 4B).
A co-immunoﬂuorescent staining of PD-1 and CD8 shows
frequent co-localization, indicating that PD-1 can be expressed
by (cytotoxic) T cells (Fig. S4). PD-L1 expression co-localized
with CD68 and CD163, supporting the idea that in our cohort
PD-L1 is not mainly expressed by tumor cells but by myeloid
cells (Fig. 4C and D).
TCGA RNA sequencing data demonstrates higher
expression of CD8A, CD3E, ITGAE (CD103), MS4A1 (CD20),
PTPRC (CD45RO), CD27,TBX21 (T-Bet) and PDCD1 (PD-1) in
POLE-mutant and MSI tumors
Next, we compared our data with the expression of above-
described immune markers in The Cancer Genome Atlas
(TCGA) cancer cohort, which was originally used to devise the
molecular classiﬁcation of EC (Fig. 5).19 Previously, we have
shown higher expression of, among others, CD3E, CD8A,
TBX21 (T-Bet) and PDCD1 (PD-1) in POLE-mutant compared
with MSI and MSS tumors.20 We now extend this analysis to
speciﬁcally compare the four proposed prognostic subgroups.19
Of the 244 informative samples, the TCGA cohort included 18
POLE-mutant, 69 MSI, 96 NSMP and 62 TP53-mutant. Analy-
sis of the RNA sequencing data of this cohort demonstrated
higher expression of CD8A, CD3E, ITGAE (CD103), MS4A1
(CD20), PTPRC (CD45RO), CD27,TBX21 (T-Bet) and
PDCD1 (PD-1) in POLE-mutant and MSI tumors compare
with NSMP and TP53-mutant. TIA-1 expression did not differ
between the four molecular subgroups. POLE-mutant ECs
showed a trend toward increased expression of CD274 (PD-L1)
(p D 0.057).
Patients with POLE-mutated and MSI tumors have higher
numbers of predicted neoantigens, regardless of their
immune inﬁltration status
The presence of a subset of POLE-mutant and MSI tumors with
a relatively low immune inﬁltration and NSMP and TP53-
mutant tumors with a relatively high immune inﬁltration led
us to evaluate the relationship between immune inﬁltrate and
numbers of predicted neoantigens within the TCGA cohort
(Fig. 6). First of all, we demonstrated the presence of higher
numbers of expected neoantigens in POLE-mutant and MSI
tumors compared with NSMP and TP53-mutant tumors
(Fig. 6A). The molecular subgroups were dichotomized accord-
ing to CD8A expression from RNAseq data, with high inﬁltra-
tion deﬁned as expression above the median of the respective
molecular subgroup. Subsequently, we quantiﬁed predicted
neoantigens for high and low inﬁltrated tumors within the
molecular subgroups (Fig. 6B). No differences were found in
the numbers of predicted neoantigens between samples with
high or low CD8A expression within the molecular subgroups.
Discussion
In this study we demonstrate the presence of high numbers of
tumor-inﬁltrating T cells in POLE-mutant and MSI tumors,
both predicted to be neoantigen-rich, from a clinically relevant
cohort of high-risk EC patients. Moreover, these two molecular
subtypes harbor high densities of PD-1- and PD-L1-expressing
immune cells, rendering them attractive candidates for immune
checkpoint inhibition strategies.
The presence of a prominent immune inﬁltrate in POLE-
mutant and MSI high-risk EC is in concordance with our previ-
ous ﬁndings in a pre-selected cohort including 47 POLE-
mutant, 49 microsatellite unstable and 54 microsatellite stable
tumors, in which we demonstrated that POLE-mutant tumors,
and to a lesser extent MSI tumors, are characterized by a robust
intratumoral T-cell response.20 These initial ﬁndings have
recently been extended to other unselected EC cohorts, in
which high densities of peritumoral and tumor-inﬁltrating
T-lymphocytes have been described in POLE-mutant
tumors.21,22,31 High expression of PD-1 and PD-L1 on intraepi-
thelial immune cells in POLE-mutant and MSI ECs has previ-
ously been suggested by Howitt et al, albeit in a cohort which
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included only three POLE-mutant cases.21 An interesting dif-
ference between the data presented by Howitt et al. and the
present study is the expression of PD-L1 on tumor cells. Howitt
et al. describe that 20% of ECs (POLE-mutant, MSI and MSS)
show PD-L1C tumor cells, whereas within our high-risk cohort
only 1 out of 116 tumors showed any expression of PD-L1 on
the tumor cells (using the same PD-L1 antibody). Our use of
tissue microarrays may have led to an underestimation of PD-
L1 expressing tumor cells, as PD-L1 expression is known to be
heterogeneously distributed.32 Moreover, consecutive full slides
of one POLE-mutant case were stained using multi-color
immunoﬂuorescence: PD-L1 expression was predominantly
found in the intratumoral stromal regions in close proximity
with PD-1C cells. Furthermore, PD-L1 expression co-localized
with CD68 and CD163, suggesting that in this case PD-L1 is
primarily expressed by myeloid cells rather than tumor cells.
PD-L1C immune cells have previously been described by
(among others) Heeren et al. and Herbst et al.; the latter also
showed that PD-L1 positivity on immune cells, but not on
tumor cells, was associated with response to immune check-
point inhibition.1,28
Comparisons of outcomes from our immunohistochemical
analyses in the TransPORTEC high-risk cohort and analyses of
the RNA sequencing data from The Cancer Genome Atlas
(TCGA) showed similar results for ﬁve out of ten markers,
namely CD3, CD8C, CD103, CD45RO and PD1. The immuno-
histochemical analyses of the TransPORTEC cohort did not
reveal signiﬁcant differences in numbers of CD20C and CD27C
cells between the four molecular subgroups, while analysis of
the TCGA cohort demonstrated increased expression of
Figure 4. Immunoﬂuorescent stainings of PD-1, PD-L1 and myeloid markers. Representative image of a POLE-mutant endometrial cancer stained with keratin (green)–
CD163 (blue)–CD68 (red) in (A), and PD-1 (green)–PD-L1 (blue) in (B). The two triple immunoﬂuorescent stainings from A and B, performed on sequentially cut slides, are
layered in (C), with single channel markers for the inset in (D), with keratin (green), PD-L1 (blue), CD68 (red) and CD163 (yellow), demonstrating the co-localization of PD-
L1 with myeloid markers.
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CD20C and CD27C cells within the POLE-mutant and MSI
subgroups. This inconsistency may be attributed to the use of a
TMA for immunohistochemical analyses of CD20C and
CD27C cells. These immune cells frequently reside in tertiary
lymphoid structures in the myometrium, which are frequently
seen in POLE-mutant tumors.20,33-35 The areas containing these
structures may not have been present in the TMA. Second, out-
comes regarding TIA-1, T-Bet and PD-L1 positivity were dis-
cordant. These differences may be due to the known
discrepancy between mRNA and protein expression.36 Another
possible explanation for these discrepancies may be the rela-
tively high proportion of clear cell EC (15.5%) within the
TransPORTEC high-risk cohort, while only endometrioid,
serous and mixed histologies were included in the TCGA study.
The presence of high numbers of CD8C and PD-1C cells in
POLE-mutant and MSI tumors may suggest the presence of
high numbers of tumor-speciﬁc T cells targeting neoantigens
within these subgroups of patients. Similarly, our analysis of
the TCGA EC cohort demonstrates that POLE-mutant and
MSI tumors are characterized by a signiﬁcantly higher number
of mutations predicted to result in major histocompatibility
complex-binding neoantigens, and a correspondingly higher
number of tumor-inﬁltrating CD8C T cells, as assessed by
CD8A mRNA levels. This link between neoantigen accumula-
tion and inﬁltration by immune cells is supported by a recent
genomic characterization of colorectal cancers, in which an
association between high neoantigen load, overall lymphocytic
inﬁltration, tumor-inﬁltrating lymphocytes and survival was
demonstrated.10
Surprisingly, the number of predicted immunogenic
mutations did not directly reﬂect the levels of CD8A mRNA
expression within each molecular subgroup (Fig. 6). Simi-
larly, in our immunohistochemical analysis, we found MSI
tumors, expected to be neoantigen-rich, with almost no signs
of CD8C T-cell inﬁltration, and p53-mutant tumors,
expected to have low numbers of neoantigens, with an
enhanced intratumoral immune response. One explanation
for this apparent discrepancy between immune inﬁltration
and the number of predicted neoantigens could be that the
nature (i.e., clonal vs subclonal) of the neoepitopes, instead
of the crude number of predicted neoantigens, determine the
degree of immune response.13 Another explanation may be
Figure 5. Expression of immune markers in according to tumor molecular subtype in TCGA series. RSEM normalized RNAseq data were log2 transformed and analyzed
according to tumor molecular subtype. Boxes represent the interquartile range (IQR), with the upper whisker indicating the 75th percentile and the lower whisker the
25th percentile. The median and mean values are indicated by a horizontal line and cross, respectively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite unstable;
NSMP, no speciﬁc molecular proﬁle; p53, p53-mutant. p < 0.05, p < 0.01, p < 0.001.
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that within our analyses only predicted binding to HLA-
A02:01 was taken into account rather than to individual
HLA alleles. Furthermore, immune responses may be
impeded by impairment of major histocompatibility complex
(MHC) class I expression due to mutations in HLA, b-2
microglobulin and JAK-1 in highly mutated ECs.20,37 There-
fore, a logical next step in understanding the interaction
between neoepitopes and immune response within the four
molecular subgroups would be the direct identiﬁcation and
characterization of tumor-speciﬁc T cells targeting these neo-
antigens, as has recently been performed by Gros et al. in
melanoma.24
With regard to the p53-mutant tumors with an enhanced
antitumor immune response despite low expected neoantigen
load, we hypothesize that this response may be aimed at self-
antigens or cancer/testis antigens instead of neoepitopes. Tak-
ing into account their unfavorable survival outcomes, further
investigation of the highly inﬁltrated p53-mutant subset will be
of great interest as this may provide new insight in the selection
of candidates for immune checkpoint therapies.
The data on mutational load, neoantigens and immune inﬁl-
tration reported by us and others suggest that checkpoint inhi-
bition may be a strategy of particular interest for treating
advanced stage patients with POLE-mutant and MSI tumors.
Figure 6. Predicted number of HLA-A2-binding neoantigens across the four molecular subgroups in The Cancer Genome Atlas endometrial cancer cohort. (A) Comparison
between the number of predicted HLA-A2 binding neoantigens in POLE-mutant, MSI, NSMP and TP53-mutant subgroups based on RNAseq. (B) Comparison between
patients with high and low inﬁltration (based on CD8A expression from RNAseq, relative to median within the group) of lymphocytes within POLE-mutant, MSI, NSMP
and TP53-mutant subgroups. The numbers of cases analyzed for each molecular subgroup are listed below the x-axis. Boxes represent the interquartile range (IQR), with
upper whisker indicating the 75th percentile and the lower whisker the 25th percentile. The median and mean values are indicated by a horizontal line and cross, respec-
tively. Abbreviations: POLE, POLE-mutant; MSI, microsatellite unstable; NSMP, no speciﬁc molecular proﬁle; p53, p53-mutant. p < 0.05, p < 0.01, p < 0.001.
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Recent case reports provide proof of principle by demonstrat-
ing the efﬁcacy of anti-PD-1 inhibitors in a limited number of
advanced stage POLE-mutant or mismatch repair deﬁcient can-
cers.7,25,26 Moreover, a Phase II trial evaluating immune related
objective responses to Pembrolizumab in patients with or with-
out mismatch repair (MMR) deﬁciency, demonstrated objective
responses in 40% of patients with MMR deﬁcient colorectal
cancer and 71% of patients with MMR deﬁcient non-colorectal
cancers (including two ECs). Contrastingly, no objective
responses were observed in the MMR proﬁcient colorectal can-
cers. Moreover, data from this study adds to the growing body
of evidence suggesting that high numbers of somatic mutations
(in this case due to MMR deﬁciency) and high numbers of
predicted neoantigens play an important role in the
sensitivity to checkpoint inhibition.11-13,15 Furthermore, an in-
depth analysis of patients treated with anti-PD-1 therapy prior-
itized PD-L1 expression as being the most closely associated
with objective tumor regression.38 Further analyses of non-res-
ponders may uncover other mutations affecting epitope presen-
tation, T-cell inﬁltration and response to checkpoint inhibition.
From a clinical point of view, as checkpoint inhibitors are
associated with signiﬁcant costs and potential toxicities, it is
essential to select individual patients that will beneﬁt from these
therapies. Patients with low/intermediate-risk disease carrying
POLE mutations have an excellent prognosis under standard
treatment, and therefore checkpoint inhibition is unlikely to be
appropriate for this group.19,39-41 However, (although infre-
quently occurring) POLE-mutant and MSI patients with recur-
ring or metastatic disease are possible candidates.7,25,26 Clinical
trials, in which high-risk EC patients are grouped according to
molecular subtype, will be required to determine clinical beneﬁt
of immunotherapy.
Importantly, the data thus far regarding POLE-mutant EC
may be applicable to other tumor types harboring POLE muta-
tions. While POLE mutations are found in 7–12% of EC, they
are also found in other malignancies including colorectal can-
cers, cancers of the brain, breast, pancreas and stomach, albeit
at lower frequencies.19,39,42-48 Although a prognostic advantage
of this mutation has now been established in glioblastoma and
stage II/III colorectal cancer, patients with recurrent or meta-
static hypermutated disease may also beneﬁt from immuno-
therapeutic strategies such as checkpoint inhibitors as
proposed for EC.7,47,49 Basket trials stratifying patients accord-
ing to tumor molecular alterations such as POLE mutations
should be initiated to investigate whether these patients may
also beneﬁt from checkpoint inhibition.
In summary, taking into account the strong immune inﬁl-
tration, high numbers of PD-1C and PD-L1C lymphocytes,
large numbers of somatic mutations and neoantigens, and the
recently demonstrated clinical efﬁcacy in these cohorts of
patients, POLE-mutant and MSI tumors are expected to beneﬁt
from checkpoint inhibition.21,25,50
Methods
Selection of patients and tissues
A previously described cohort of 116 high-risk EC patients was
used in this study (Table 1).42 In brief, tumor tissues from
high-risk EC patients were selected from partner institutions of
the TransPORTEC consortium using inclusion criteria of the
PORTEC-3 study. Patients included in the PORTEC-3 had EC
with one of the following FIGO 2009 stages and grade: 1A
grade 3 with myometrial and lymphovascular space invasion;
IB grade 3; II, IIIA or IIIC; IIIB if only parametrial invasion;
stage IA (with invasion), 1B, II or III with serous or clear cell
histology.51
Construction of tissue microarray
Morphologically representative parafﬁn-embedded tissue
blocks containing at least 70% tumor cells were selected by two
experienced gyneco-pathologists (VS and TB). The selected
tumor blocks were used to construct (and validate) a Tissue
Microarray (TMA) as previously described.42 One millimeter-
sized tumor (center of the tumor) and tumor/stroma (invasive
margin) cores of each tumor block were randomly distributed
on the TMA in triplicate.
Assessment of POLE, MSI, p53 and NSMP status
Classiﬁcation of patients into the four molecular subgroups was
performed as previously described.42 In brief, tumor DNA iso-
lation was performed fully automated using the Tissue Prepara-
tion System (Siemens Healthcare Diagnostics).52 Bi-directional
Sanger sequencing was used to screen exons 9, 13 and 14 of the
POLE exonuclease domain for somatic mutations. Microsatel-
lite instability and p53 mutational status were determined as
previously described.42,53
Immunohistochemistry
TMA sections were deparafﬁnized and rehydrated. Antigen
retrieval was performed using 0.01M citrate buffer pH 6.0, and
endogenous peroxidase activity was blocked. Slides were incu-
bated overnight at room temperature (CD3, TIA-1, T-Bet and
PD-1), for 1 h at room temperature (CD8C, CD20) or over-
night at 4 C (CD103) with primary antibodies against CD3
(1:100, clone PS-1, Diagnostic BioSystems), CD8C (1:50, clone
C8/144B, DAKO), CD20 (1:200, clone L26, DAKO), CD103
(1:200, Integrin aEb7, Abcam), TIA-1 (1:200, clone 2G9A10F5,
Beckman Coulter), T-bet (1:400 in 10% normal goat serum, sc-
21003, Santa Cruz Biotechnology), PD-1 (1:200, AF1086,
R&D), and PD-L1 (1 mg/mL, clone E1L3N, Cell Signaling
Technology). Slides were incubated with BrightVision Poly-
HRP (poly-HRP-GAM/R/R, DPV0110HRP, Immunologic;
CD3, TIA-1, T-bet), a goat HRP-polymer kit (GHP516H, Bio-
care Medical; PD-1), anti-mouse secondary antibody (K4007,
DAKO, CD8C, CD20) or anti-rabbit secondary antibody
(K4011, DAKO, CD103) for 30 min. For CD103, a slightly dif-
ferent method using avidin/biotin blocking was used as
described previously.54 PD-L1 staining was performed using
the Ventrana Discovery Ultra Platform for automatic staining,
detection was performed using the Discovery Amp-HQ kit
(tyramide-based ampliﬁcation). Antibody binding was visual-
ized with 3,30-diamino-benzidine-tetrahydrochloride (DAB)
and haematoxylin counterstaining. Slides were dehydrated and
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mounted before digitalization (Ultra Fast Scanner 1.6 RA. Phi-
lips or ScanScope, Aperio technologies) and analysis.
Quantiﬁcation of IHC
Total numbers of CD3C, CD8C, CD103C, CD27C, TIA-1C,
T-BetC, CD20C, CD45ROC and PD-1C cell numbers were
quantiﬁed per core. The percentage of tumor and stroma sur-
face area within each core were estimated, and used to extrapo-
late cell counts to 100% surface area. Cores taken from the
tumor center were included in the analysis if at least two out of
the three cores contained >20% tumor. Cores from the inﬁltra-
tive margin were included in the analysis if at least two out of
the three cores contained >20% stroma and if there was tumor
tissue present. Average cell counts per 100% surface area were
recorded for the tumor center and inﬁltrative margin. Slides
were counted manually by two individuals (FE and IG) that
were blinded for other clinicopathological data. Inter-observer
variation was evaluated by Spearman rank correlation (median
R2 0.935, range 0.682–0.988).
Quantiﬁcation of PD-L1 was evaluated on tumor-inﬁltrating
immune cells and tumor cells as previously described.1 In brief,
the proportion of PD-L1 expressing tumor cells (tumor score)
was noted as a percentage of the total number of tumor cells
within that core. Due to very low expression of PD-L1 it was
decided to consider any expression of PD-L1 on tumor cells
as positive. Furthermore, the percentage of tumor-inﬁltrating
immune cells (immune score) with moderate to strong PD-
L1 expression was registered. Immune cells were deﬁned
positive when cells displayed clearly visible cytoplasmic and/
or membranous staining. Patients were included in the anal-
ysis if at least two out of three cores were evaluated; the ﬁnal
score was based on the core with the highest PD-L1 expres-
sion. For the analyses of the immune score, PD-L1 positivity
was deﬁned as >1% (based on the median score in the
cohort).
Immunoﬂuorescence
Three combinations of multi-color immunoﬂuorescent stain-
ings were performed as described previously.55 The ﬁrst combi-
nation consisted of anti-CD163 (polyclonal rabbit, ab87099,
Abcam), anti-CD68 (monoclonal mouse IgG2a, clone 514H12,
ABDserotec) and anti-keratin (monoclonal mouse IgG1, clone
AE1/AE3, MAB3412, Millipore). The second combination con-
sisted of anti-PD-L1 (polyclonal rabbit, clone SP142, Roche)
and anti-PD1 (monoclonal mouse IgG1, clone NAT105,
Abcam), and the third consisted of anti-CD8C (mouse mono-
clonal IgG2b, clone 4B11, Novo Castra) and anti-PD-1 (poly-
clonal goat, R&D Systems).
Table 1. Clinicopathological characteristics of the high-risk endometrial cancer patient cohort.
All patients POLE-mutant MSI NSMP p53-mutant
N D 116 N D 15 N D 19 N D 42 N D 40
N % N % N % N % N % p-value
Age at diagnosis (years)
Mean (range) 66 (21–85) 61 (49–80) 65 (49–82) 64 (21–84) 71 (45–85) 0.004
Stage
I 42 36.2 8 53.3 5 26.3 16 38.1 13 32.5 0.246
II 21 18.1 3 20.0 2 10.5 12 28.6 4 10.0
III 41 35.3 3 20.0 10 52.6 11 26.2 17 42.5
IV 11 9.5 1 6.7 2 10.5 3 7.1 5 12.5
Unknown 1 0.9 0 0.0 0 0.0 0 0.0 1 2.5
Tumor type
Endometrioid 86 74.1 14 93.3 17 89.5 35 83.3 20 50.0 <0.001
Serous 12 10.3 0 0.0 0 0.0 0 0.0 12 30.0
Clearcell 18 15.5 1 6.7 2 10.5 7 16.7 8 20.0
Grade
1 13 11.2 0 0.0 2 10.5 8 19.0 3 7.5 0.036
2 5 4.3 1 6.7 3 15.8 1 2.4 0 0.0
3 98 84.5 14 93.3 14 73.7 33 78.6 37 92.5
Lymphovascular space invasion
Yes 55 47.4 6 40 15 78.9 18 42.9 16 40 0.103
No 40 34.5 9 60.0 2 10.5 18 42.9 11 27.5
Unknown 21 18.1 0 0.0 2 10.5 6 14.3 13 32.5
Depth of myometrial invasion
<50% 23 19.8 4 26.7 2 10.5 6 14.3 11 27.5 0.261
>50% 87 75.0 11 73.3 17 89.5 33 78.6 26 65.0
Unknown 6 5.2 0 0.0 0 0.0 3 7.1 3 7.5
Adjuvant therapy
Yes 82 70.7 14 93.3 15 78.9 33 78.6 20 50.0 0.134
No 10 8.6 1 6.7 1 5.3 2 4.8 6 15.0
Unknown 24 20.7 0 0.0 3 15.8 7 16.7 14 35.0
Characteristics are shown for the whole group, as well as for each of the molecular subgroups analyzed. Abbreviations: MSI, microsatellite unstable; NSMP, no speciﬁc
molecular proﬁle.
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In short, after slides were deparafﬁnized and rehydrated,
antigen retrieval was achieved by microwave oven treatment in
a Tris–EDTA buffer at pH 9.0. Slides were incubated with the
listed primary antibodies overnight. The following secondary
Alexa Fluor labeled antibodies were used for the CD163–
CD68–keratin and PD-L1–PD-1 combinations: 647 goat anti-
rabbit, 546 goat anti-mouse IgG2a, and 488 goat anti-mouse
IgG1 (all from Invitrogen, Life Technologies, Carlsbad, USA).
Donkey anti-goat 488 and donkey anti-mouse IgG 647 were
used for PD-1/CD8C detection. The slides were counterstained
with DAPI and coverslipped. Immunoﬂuorescent images were
acquired with an LSM700 confocal laser scanning microscope
equipped with an LCI Plan-Neoﬂuar 25£/0.8 Imm Korr DIC
M27 objective (Zeiss, G€ottingen, Germany). Double or triple
positivity of cells in the center of the tumor as well as at the
invasive margin was determined using LSM Image Browser
(version 4.2.0.121, Zeiss). Images from the two triple immuno-
ﬂuorescent stainings were merged using Adobe Photoshop CS6.
TCGA RNA sequencing
TCGA RNAseq analysis was performed as previously
reported.19,20 Data were downloaded from FireBrowse on
November 11, 2014 (http://ﬁrebrowse.org/?cohortDUCECand
download_dialogDtrue). In total, 245 samples with RSEM nor-
malized data were available for analysis.
Prediction of antigenic neoepitopes
Prediction of antigenic neoepitopes was performed as previ-
ously reported.20 In brief, an algorithm was developed to esti-
mate the immunogenicity of individual tumors in which the
following considerations were taken into account: (i) to gener-
ate a functional neoepitope a missense mutation must be
expressed; (ii) most functional neoepitopes are predicted to
bind MHC class I molecules (IC50 < 500 nM) by NetMHC-
Pan.8,56,57; (iii) the likelihood that a neoepitope is antigenic is
reduced if the corresponding wild-type peptide also binds the
MHC with similar afﬁnity as T cells to the epitope may be cen-
trally deleted or tolerized.58 Our strategy was similar to that
reported by others.8,13,57,59 For each tumor all possible 9mers
for every missense mutation in expressed genes (deﬁned as
non-zero reads from RNAseq) and the binding afﬁnity of the
mutant and corresponding wild-type peptide for HLA-A02:01
were calculated using NetMHCPan 2.8.56 If several peptides
had an IC50 <500 nM, the strongest binder was used for analy-
sis. We deﬁned antigenic mutations as neoepitopes predicted to
bind MHC molecules (IC50 < 500 nM) for which the corre-
sponding wild-type peptide was not predicted to bind MHC
(IC50 > 500 nM).
Statistical methods
Comparison between clinicopathological characteristics of the
four molecular subgroups was made using Kruskal–Wallis fol-
lowed by Mann–Whitney U (for age) and x2 tests (for all other
variables). Correlations between immunohistochemical stain-
ings and the four molecular subgroups were evaluated using
Kruskal–Wallis followed by Mann–Whitney U tests. The same
method was used to evaluate correlations between RNA expres-
sion from the TCGA cohort of immune-related genes and the
four molecular subgroups. Additionally, analyses were per-
formed combining POLE-mutant and MSI samples vs NSMP
and p53-mutant samples. All tests were performed two-sided.
Signiﬁcance was deﬁned as a p-value of < 0.05. Statistical anal-
yses were performed using IBM SPSS version 22 (SPSS, Inc.,
Chicago, USA) and GraphPad Prism (GraphPad Software, Inc.,
CA, USA).
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